Analysts Set Liquidia Co. (NASDAQ:LQDA) Price Target at $27.13

Shares of Liquidia Co. (NASDAQ:LQDA - Get Free Report) have been assigned a consensus rating of "Buy" from the nine ratings firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, six have issued a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $25.56.

Several research firms have recently issued reports on LQDA. Scotiabank reaffirmed an "outperform" rating on shares of Liquidia in a research note on Monday, May 5th. Oppenheimer cut shares of Liquidia from a "market perform" rating to an "underperform" rating and set a $13.00 price objective for the company. in a research report on Monday. Needham & Company LLC reiterated a "buy" rating and set a $25.00 price objective on shares of Liquidia in a research report on Wednesday. HC Wainwright reiterated a "buy" rating and set a $29.00 price objective on shares of Liquidia in a research report on Monday, May 12th. Finally, Raymond James increased their price objective on shares of Liquidia from $27.00 to $29.00 and gave the stock a "strong-buy" rating in a research report on Friday, May 9th.

Liquidia Trading Down 2.1%

NASDAQ:LQDA traded down $0.36 on Friday, hitting $16.66. The company had a trading volume of 1,759,797 shares, compared to its average volume of 1,041,423. The stock has a market capitalization of $1.42 billion, a price-to-earnings ratio of -10.22 and a beta of 0.24. The firm has a 50 day moving average of $14.72 and a two-hundred day moving average of $13.50. Liquidia has a 52 week low of $8.26 and a 52 week high of $19.41.

Liquidia (NASDAQ:LQDA - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.03). The company had revenue of $3.12 million during the quarter, compared to the consensus estimate of $3.23 million. Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. As a group, equities analysts forecast that Liquidia will post -1.51 EPS for the current year.

Insider Activity

In other news, CEO Roger Jeffs sold 14,130 shares of the stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $13.57, for a total transaction of $191,744.10. Following the completion of the transaction, the chief executive officer now directly owns 1,006,420 shares of the company's stock, valued at $13,657,119.40. This represents a 1.38% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Jason Adair sold 1,856 shares of the company's stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $13.57, for a total transaction of $25,185.92. Following the sale, the insider now owns 184,304 shares in the company, valued at $2,501,005.28. The trade was a 1.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 33,138 shares of company stock worth $450,233. Company insiders own 26.50% of the company's stock.

Hedge Funds Weigh In On Liquidia

Institutional investors have recently made changes to their positions in the stock. Hurley Capital LLC bought a new position in shares of Liquidia in the 1st quarter worth $32,000. GAMMA Investing LLC raised its position in Liquidia by 65.6% in the 1st quarter. GAMMA Investing LLC now owns 2,961 shares of the company's stock worth $44,000 after purchasing an additional 1,173 shares during the period. Steward Partners Investment Advisory LLC purchased a new position in Liquidia in the 4th quarter worth $59,000. Summit Investment Advisors Inc. raised its position in Liquidia by 35.0% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company's stock worth $78,000 after purchasing an additional 1,719 shares during the period. Finally, Quarry LP purchased a new position in Liquidia in the 1st quarter worth $79,000. Institutional investors own 64.54% of the company's stock.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).